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Weight gain in pregnancy and risk of maternal hyperglycemia
Sharon J. Herring, Emily Oken, Sheryl L. Rifas-Shiman, Janet W. Rich-Edwards, 
Alison M. Stuebe, Ken P. Kleinman, and Matthew W. Gillman
Abstract
OBJECTIVE—The purpose of this study was to examine associations of weight gain from
prepregnancy to glycemic screening with glucose tolerance status.
STUDY DESIGN—Main outcomes were failed glycemic screening (1-hour glucose result ≥ 140
mg/dL) with either 1 high value on 3-hour oral glucose tolerance testing (impaired glucose
tolerance in pregnancy) or ≥ 2 high values on 3-hour oral glucose tolerance testing (gestational
diabetes mellitus). We performed multinomial logistic regression to determine the odds of these
glucose intolerance outcomes by quartile of gestational weight gain among 1960 women in Project
Viva.
RESULTS—Mean gestational weight gain was 10.2 ± 4.3 (SD) kg. Compared with the lowest
quartile of weight gain, participants in the highest quartile had an increased odds of impaired
glucose tolerance in pregnancy (adjusted odds ratio, 2.54; 95% confidence interval, 1.25–5.15),
but not gestational diabetes mellitus (odds ratio, 0.93; 95% confidence interval, 0.50–1.70).
CONCLUSION—Higher weight gain predicted impaired glucose tolerance in pregnancy, but not
gestational diabetes mellitus.
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Gestational diabetes mellitus (GDM) complicates 1–14% of pregnancies1 and is associated
with increased risk of adverse perinatal outcomes1–5 as well as longer-term complications of
obesity and type 2 diabetes mellitus in both mothers and children.2,3,6–8 Maternal
hyperglycemia less severe than that used to define overt diabetes mellitus is also related to
perinatal complications.8–12 These effects may be reduced through treatment.13 Given the
rise in GDM incidence over the past decade,14 research to identify modifiable determinants
of glucose intolerance has become a public health priority.
Pregravid obesity is the most well-documented modifiable risk factor for GDM.15,16 Several
studies additionally suggest that the risk of glucose intolerance increases with weight gain
just prior to pregnancy.16–19 Although the exact mechanisms by which weight gain and
obesity promote incident diabetes mellitus are not understood fully, a combination of
adiposity-generated insulin resistance and deterioration in pancreatic beta cell function are
likely to blame.20–22 Given that fat comprises approximately 30% of weight gain in
pregnancy,23–25 during which time women experience physiologic reductions in insulin
sensitivity, 26 it seems plausible that greater gestational weight gain would also increase the
risk of GDM.
Limited data exist regarding the relationship between gestational weight gain and maternal
hyperglycemia. Saldana et al27 found no association between total weight gain and glucose
tolerance until the end of the second trimester; however, when the authors analyzed
gestational weight gain as a ratio of actual gain compared with recommended gain, they
found a modestly increased risk of impaired glucose tolerance (IGT) in pregnancy solely in
overweight women, but no association with GDM. A more recent trial revealed 20%
reductions in serum insulin and leptin levels at 27 weeks of gestation among obese women
who were assigned randomly to restrict weight gain during pregnancy compared with
control subjects; however, the small sample size precluded the authors’ ability to make
conclusions about risk of incident GDM.28
To clarify the relationship between gestational weight gain and maternal hyperglycemia, we
used data from a longitudinal cohort study of pregnant women. We evaluated associations of
both total gestational weight gain before glycemic screening and trimester-specific weekly
rate of gain with glucose tolerance status.
Materials and Methods
Study population and design
Study subjects were recruited into Project Viva at their first prenatal visit from 1 of 8 urban
and suburban obstetric offices that were associated with a multispecialty group practice in
eastern Massachusetts from 1999–2002, as summarized previously.29,30 Eligibility criteria
included fluency in English, gestational age of <22 weeks, and a singleton pregnancy. All
mothers provided written informed consent, and all procedures were in accordance with
ethical standards for human experimentation.31 Institutional review boards of the
participating sites approved the study.
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Of the 2128 women who delivered a live singleton infant, 81 women had a body mass index
(BMI) < 18.5 kg/m2 (underweight) and were excluded, because they are at low risk for
glucose intolerance and only 2 underweight participants had GDM in our cohort. We also
excluded women who had a history of type 1 or type 2 diabetes mellitus (n = 16), who were
missing information on prepregnancy diabetes status (n = 22) or BMI (n = 7), or who had
incomplete data on glucose tolerance testing (n = 17) or weight gain (n = 25) in pregnancy,
which left 1960 women in this analysis. Women who were not included were somewhat
younger (30.5 vs 31.9 years old), less likely to be white (53% vs 67%), and less likely to be
of normal weight (46% vs 61%), but did not differ in mean glucose level at glycemic
screening or GDM in the index pregnancy.
Gestational weight gain
We calculated total gestational weight gain before second-trimester glycemic screening as
the difference between the weight that was recorded at the glycemic screen and self-reported
prepregnancy weight. If no measure of weight was available at the time of glycemic
screening, we used linear interpolation between the 2 surrounding weights to estimate the
weight on that day. Additionally, we computed the rate of weight gain per week from
prepregnancy to 13 weeks (91 days) gestation, and from 13 weeks of gestation to glycemic
screening. We used linear interpolation to estimate the weight at 13 weeks of gestation if it
was not available from the obstetric record.
We previously reported findings from a validation study in our cohort that compared self-
reported prepregnancy weights with clinically measured weights among a sample of 170
women who had weight recorded in the medical record within 3 months before their last
menstrual period. We found that the relationship between the 2 weights was linear and
tightly correlated (r = 0.99), with a mean systematic underreport of 1 kg that did not vary by
maternal race/ethnicity, gestational age at enrollment into the study, or weight itself.29
Glycemic screening and classification of glucose tolerance status
Participating women underwent routine glycemic screening for GDM between 26–28 weeks
of gestation with a nonfasting oral glucose challenge test (GCT), in which venous blood was
sampled 1 hour after a 50-g oral glucose load. If the 1-hour glucose result was ≥ 140 mg/dL,
the participant was referred for a 100-g fasting glucose 3-hour tolerance test (OGTT).
Normal OGTT results were a blood glucose level of <95 mg/dL at baseline, < 180 mg/dL at
1 hour, < 155 mg/dL at 2 hours, and < 140 mg/dL at 3 hours.1
Based on a combination of the GCT and OGTT results, we focused on 2 categories of
glucose intolerance: (1) IGT in pregnancy was defined as failing the GCT (1-hour glucose
result of ≥ 140 mg/dL) with 1 high value on the 3-hour OGTT, and (2) GDM was defined as
failing the GCT (1-hour glucose result of ≥ 140 mg/dL) with ≥ 2 high values on the 3-hour
OGTT. We chose these definitions of glucose intolerance to allow for comparison with
previously published work.27 Women whose GCT results were <140 mg/dL did not have
OGTT testing and comprised the referent group (normal glucose tolerance [NGT]). We also
evaluated the remaining mothers who had GCT results of ≥140 mg/dL, but no high values
on the OGTT, separately from mothers with NGT results (which differs from the work of
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Saldana et al27), because data are mixed regarding differences in outcomes for this group vs
NGT or IGT in pregnancy.8,32,33
Assessment of covariates
Using a combination of interviews and questionnaires at the first study visit (~ 10 weeks of
gestation), we collected information on maternal race/ethnicity, age, parity, history of GDM
in a previous pregnancy, history of diabetes mellitus in the participant’s own mother, and
smoking habits. We calculated BMI (kg/m2) from self-reported prepregnancy height and
weight and categorized women as either normal weight (18.5–24.9 kg/m2), overweight
(25.0–29.9 kg/m2), or obese (≥ 30 kg/m2).34 Gestational age at glycemic screening was
calculated as the difference between the date of a woman’s GCT result and her last
menstrual period (adjusted to reflect gestational age that had been calculated by second-
trimester ultrasound examination, if the 2 estimates differed by >10 days). As part of the
early pregnancy questionnaire, participants also reported their physical activity habits during
the 12 months before pregnancy. Vigorous activity was of primary interest because results
from Project Viva have shown reductions in risk of both GDM and excessive gestational
weight gain among women who perform any vigorous activity before pregnancy.35,36 In mid
pregnancy, we assessed diet, time spent watching television, and early pregnancy leisure-
time physical activity by questionnaire; however, we did not include dietary factors or
television-viewing behavior in the present analysis because neither was associated with
glucose tolerance in this cohort.35,37
Statistical analysis
Because we found moderate variation among participants in timing of glycemic screening
(mean, 27.7 weeks; range, 9.3–38.0 weeks), we used a linear regression model to compute
our weight gain variable that was adjusted for gestational age at screening. Next, we ranked
gestational age-adjusted weight gain into quartiles. We then used multinomial regression38
to examine associations of participant characteristics and quartiles of weight gain with
glucose tolerance status, which was stratified initially by maternal prepregnancy BMI
category. This method calculates the odds of having glucose intolerance, compared with the
reference group, NGT. Because we did not find substantial differences in the gestational
weight gain-glucose intolerance relationship by BMI after stratification or with the addition
of an interaction term (P = .83), we proceeded without stratification.
We included, as covariates, participant characteristics that were of a priori interest or
confounded the relationship between weight gain and glucose tolerance status: maternal age,
prepregnancy BMI category, race/ethnicity, and history of GDM in a previous pregnancy.
Adjustment for other characteristics that included family history of diabetes mellitus,
smoking habits, pregravid vigorous activity level, and activity during pregnancy did not
result in material changes in the magnitudes of the observed associations between weight
gain and outcomes; therefore, we did not include these variables in the final models.
Because women with previous GDM are at a higher risk of GDM in a subsequent pregnancy
and may modify their weight gain accordingly, we repeated our analysis after excluding
women who reported a history of GDM (n = 36).
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We additionally fit a separate multinomial regression model to assess the relationship
between rate of weight gain with glucose tolerance status. To better understand the
interactive and independent effects of rate of weight that was gained in early (< 13 weeks of
gestation) and mid pregnancy (≥ 13 weeks of gestation, but before glycemic screening), we
dichotomized the rate of weight gain during each period at the median and created 4
categories: (1) those women with a low rate of gain in both periods, (2) those women with
low early pregnancy gain but high gain in mid pregnancy, (3) those women with high early
pregnancy gain but low gain in mid pregnancy, and (4) those women with a high rate of gain
in both periods. Moreover, to allow for comparison with previously published work,27 we
calculated each participant’s weight gain ratio before glycemic screening (that is, the ratio of
actual weight gain to expected gain based on recommendations from the Institute of
Medicine over the same time period).25,39 We used SAS software (version 9.1; SAS
Institute, Cary, NC) to carry out all analyses.
Results
Among the 1960 participants, mean age was 31.9 ±5.1 (SD) years, and mean prepregnancy
BMI was 25.1 ± 5.4 kg/m2. One-third of participants were nonwhite, which included 16%
black and 8% Hispanic women. After adjustment for gestational age at glycemic screening,
mean weight gain before screen was 10.2 ± 4.3 kg (range, −9.4 kg to 29.1 kg). Overall,
women who were younger, black, obese, or had a previous pregnancy with GDM gained less
weight before glycemic screening (Table 1). We found no differences in mean nonfasting
screening glucose level or family history of diabetes mellitus across quartiles of gestational
weight gain. Mothers who were less active or quit smoking before pregnancy were more
likely to gain in the upper quartile of weight before glycemic screening (data not shown).
We identified 1615 women (82%) with NGT, 174 women (9%) with GCT ≥ 140 mg/dL but
no high values on the OGTT, 61 women (3%) with IGT in pregnancy, and 110 women (6%)
with GDM. A large proportion of women (43%) who eventually were diagnosed with IGT in
pregnancy gained in the highest quartile of weight before glycemic screening, in contrast to
the relatively equal distribution of NGT mothers across all 4 quartiles of weight gain (Table
1).
After adjustment for gestational age at glycemic screening, age, race/ethnicity, history of
GDM, and prepregnancy BMI category, gestational weight gain in the highest quartile
(12.9–29.1 kg), compared with the lowest (−9.4 kg to 7.9 kg), was associated with increased
risk of IGT in pregnancy (odds ratio [OR], 2.54; 95% confidence interval [CI], 1.25–5.15),
but not GDM (OR, 0.93; 95% CI, 0.50–1.70; Figure 1). The exclusion of women with a
history of GDM in a previous pregnancy did not change the results materially (adjusted OR
for IGT in pregnancy, 2.64; 95% CI, 1.28–5.45, and for GDM, 0.94; 95% CI, 0.50–1.77).
Furthermore, results were essentially unchanged when we analyzed weight gain as the ratio
of observed-to-expected gain, as done elsewhere27 (data not shown). We found no
association between the highest quartile of gestational weight gain and lowest quartile of
weight gain among women who had GCT results ≥140 mg/dL, but no high values on the
OGTT (OR, 1.19; 95% CI, 0.72–1.97).
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Additional predictors of IGT in pregnancy on multivariate analyses were BMI (OR, 1.89;
95% CI, 1.04–3.44 for overweight vs normal weight) and history of GDM (OR, 7.68; 95%
CI, 1.46–40.4 for previous GDM vs no history of GDM). Participant characteristics were
associated with GDM in the anticipated directions and included race/ethnicity (OR, 2.27;
95% CI: 1.13–4.57 for Hispanic vs non-Hispanic white), age (OR, 1.08; 95% CI, 1.03–1.13
per year), BMI (OR, 1.92; 95% CI, 1.13–3.26 for overweight vs normal weight; OR, 3.92;
95% CI, 2.22–6.73 for obese vs normal weight), and history of GDM (OR, 80.3; 95% CI,
19.8–217 for previous GDM vs no history of GDM).
We next explored the relationship of trimester-specific rate of weight gain with IGT in
pregnancy and GDM. Median rate of weight that was gained in early pregnancy (< 13 weeks
of gestation) was 0.22 kg/wk, and median rate of weight that was gained in mid pregnancy
(≥ 13 weeks of gestation until glycemic screening) was 0.50 kg/wk. Compared with women
who experienced low weight gains in early and mid pregnancy, those women with high
gains in both periods had the greatest risk of IGT in pregnancy (adjusted OR, 2.14; 95% CI,
1.04–4.42; Table 2). Women whose rate of weight gain was high in the first trimester but
low in the second (adjusted OR, 1.40; 95% CI, 0.65–3.02), or vice versa (adjusted OR, 1.20;
95% CI, 0.52–2.77) did not have an increased risk of IGT in pregnancy. We observed no
association between the timing of weight gain and GDM, although there was a trend toward
a greater risk of the development of GDM among mothers with higher rates of weight gain
that was isolated to early pregnancy (Table 2).
Comment
In this cohort study that included almost 2000 pregnant women, we found that greater
gestational weight gain prior to glycemic screening was associated with an increased risk of
IGT in pregnancy. The risk of IGT in pregnancy was most pronounced among women with
a high rate of weight gain in both early and mid pregnancy. Adjustment for important
predictors of both gestational weight gain and glucose intolerance (namely age,
prepregnancy BMI category, race/ethnicity, and history of GDM)strengthened the
association between weight gain and IGT in pregnancy. We did not observe an association
between weight gain and frank GDM.
Our findings are similar to both prospective cohort and clinical trial work that examined the
relationship between gestational weight gain and glucose intolerance, although we found no
interaction between prepregnancy BMI and weight gain in relation to IGT in pregnancy.
Saldana et al27 found a 2-fold increased risk of IGT in pregnancy among overweight women
in the Pregnancy, Infection and Nutrition (PIN) cohort with higher gestational weight gain
ratios, but did not observe a similar increase in risk of GDM. A more recent cohort study
also revealed a positive relationship between weight gain in excess of Institute of Medicine
guidelines and the development of milder states of glucose intolerance, although these
findings were limited to Hispanic women with a BMI of ≥ 35 kg/m2.40 In a clinical trial
among obese Danish women, Wolff et al28 found 20% reductions in serum insulin and leptin
levels at 27 weeks of gestation, along with 8% reductions in fasting blood glucose at 36
weeks of gestation, in those women who were assigned randomly to a dietary counseling
intervention to restrict weight gain to 6–7 kg in pregnancy. The authors, however, saw no
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reduction in the risk of incident GDM, which suggests that changes in weight during
pregnancy may have a greater impact on more moderate levels of glucose intolerance, which
is consistent with our findings.
The large body of literature that describes associations between weight gain and risk of
hyperglycemia in nonpregnant populations provides some insight into the biologic basis of
our results.41–43 Adipose tissue actively participates in energy homeostasis through
alterations in food-intake regulatory signals, including insulin and leptin.44,45 There may be
a ceiling effect for the body’s response to leptin and insulin, above which these hormones
have no effect, and individuals will consume more energy, gain excess weight, and
experience a persistent state of hyperglycemia despite high circulating hormone levels. 45,46
We speculate that, because women gained more weight in early and mid pregnancy in our
cohort, a moderate state of glucose intolerance resulted, which likely reflects a similar set of
neuroendocrine changes that occur in the pregnant state. However, we did not find weight
gain to be predictive of frank GDM, the most severe form of glucose intolerance in
pregnancy. It is unclear whether this finding is related to other, unmeasured factors in our
cohort (such as β-cell exhaustion or pregnancy-specific alterations in insulin resistance47,48)
that predispose women to GDM independent of weight-related changes. Alternatively,
mothers who eventually develop GDM may enter pregnancy already in a state of profound
insulin resistance49,50 that leads to less weight gain over the course of gestation, as detailed
in longitudinal studies of the Pima Indian population.51 It is possible that the timing or
pattern of metabolic changes responsible for frank GDM is different from changes that
predict moderate states of glucose intolerance in pregnancy.50,52
We also observed that higher levels of gestational weight gain were not associated with
GCT results of ≥ 140 mg/dL but no high values on the OGTT, which may reflect similarities
between these participants and women with NGT, particularly with regard to longer term
offspring outcomes.8 Two recent studies, however, found that mothers who failed glycemic
screening but passed the OGTT were at increased risk of pregnancy-induced hypertension,
cesarean section delivery because of fetal distress, and 3-month postpartum reductions in
insulin sensitivity, compared with those women with NGT in pregnancy.32,33 Future work
must continue to assess whether these 2 groups share similar predictors and outcomes.
Our study has a number of strengths that include the use of several different measures of
gestational weight gain before glycemic screening, adjustment for variation in gestational
age at glycemic screen, and inclusion of multiple potential confounding variables.
Nevertheless, our findings must be interpreted within the context of the study design. One
limitation is the use of self-reported pregravid weight in early pregnancy to calculate our
measures of gestational weight gain and BMI category. Because prepregnancy weight was
self-reported, it is likely to be underestimated; therefore, gestational weight gain may be
overestimated. However, our validation study indicated that ranking of individuals is
preserved.29 Moreover, we collected prepregnancy weight before women knew their glucose
test results, further reduced the possibility of bias. Other limitations include the
generalizability of our findings, because our cohort was older and mostly white. Women
with abnormal GCT results, but no high values on the OGTT at 26–28 weeks of gestation
were not retested routinely in the third trimester of pregnancy, which may have resulted in
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misclassification of glucose tolerance status because of the possibility of later conversion to
IGT or GDM. We also had small absolute numbers of women with IGT in pregnancy in our
sample that limited our ability to do multivariable-adjusted stratified analyses, which may
explain the lack of effect modification by prepregnancy BMI that was found in our study.
In summary, we found that higher weight gain before glycemic screening predicted IGT in
pregnancy. Because glucose intolerance less severe than that used to define overt diabetes
mellitus is related to clinically important perinatal disorders,8–12 strategies to prevent
maternal hyperglycemia are critical to the design of interventions to improve outcomes in
both mothers and their infants. Our results suggest that reducing pregnancy weight gain may
be 1 effective strategy and call for more intervention work to test whether changes in
gestational weight gain before second-trimester glycemic screening leads to decreased rates
of IGT in pregnancy.
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